Summarized by Masters of Longevity from PR Newswire.
Company submitted sNDA after a Phase 3 trial showed efficacy in PGTC seizures.
Key Takeaways
- Phase 3 found cenobamate reduced PGTC seizures versus placebo.
- Most adverse events were mild to moderate and expected.
- Company reported sNDAs for PGTC and pediatric focal-onset.
